Seres Therapeutics
MCRB
148 hedge funds and large institutions have $642M invested in Seres Therapeutics in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 20 closing their positions.
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
18% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 40
16% more capital invested
Capital invested by funds: $554M → $642M (+$88.9M)
11% more funds holding
Funds holding: 133 → 148 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 4.34% → 4.2% (-0.14%)
9% less call options, than puts
Call options by funds: $3.72M | Put options by funds: $4.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$10.3M |
| 2 |
Millennium Management
New York
|
+$7.76M |
| 3 |
Renaissance Technologies
New York
|
+$5.93M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.72M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$5.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$41.5M |
| 2 |
Two Sigma Investments
New York
|
-$7.41M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.36M |
| 4 |
JP Morgan Chase
New York
|
-$4.53M |
| 5 |
SG Americas Securities
New York
|
-$4.11M |
MCRB Hedge Fund Activity: Q4 2021 in Review
148 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2021, worth a combined $642M — up 16% from $554M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MCRB positions and 20 closed out — a net gain of 17 holders — while 47 added to existing stakes and 40 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $10.3M. The largest seller was State Street, cutting an estimated $41.5M.
- 148 institutional investors held Seres Therapeutics (MCRB) as of Q4 2021, up from 133 in Q3 2021.
- Funds reported $642M of Seres Therapeutics stock for Q4 2021, up 16% quarter-over-quarter.
- 37 funds opened new Seres Therapeutics positions in Q4 2021 and 20 closed out, a net change of +17 holders.
- The largest Seres Therapeutics buyer in Q4 2021 was Jacobs Levy Equity Management, an estimated $10.3M added.
- The largest Seres Therapeutics seller in Q4 2021 was State Street, an estimated $41.5M sold.
Based on aggregated 13F filings for Q4 2021.